Clinical Outcomes of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy

• Główni autorzy: Wasim S. El Nekidy (Autor), Mooza Al Ali (Autor), Emna Abidi (Autor), Rania El Lababidi (Autor), Diaa Alrahmany (Autor), Islam M. Ghazi (Autor), Mohamad Mooty (Autor), Fadi Hijazi (Autor), Muriel Ghosn (Autor), Jihad Mallat (Autor)
• Format: Książka
• Wydane: MDPI AG, 2024-07-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

The optimal doses of ceftazidime-avibactam (CZA) and ceftolozane-tazobactam (C/T) for treating multidrug-resistant (MDR) Pseudomonas aeruginosa (PSA) in patients utilizing renal replacement therapy (RRT) are not well established. Hence, the objective of this study is to evaluate the clinical outcome...